Prospective, explorative, randomized, controlled, double-blind, cross-over phase IIa clinical trial to investigate safety and tolerability as well as potential clinical effects of BC007 in patients with post-COVID syndrome.

The University Hospital of Erlangen recently completed a phase 2a investigator-initiated trial (reCOVer) of rovunaptabin in 30 patients with post-COVID syndrome (EudraCT 2022-001781-35). The study confirmed the safety and tolerability of rovunaptabin, with improvements in fatigue and post-exertional malaise (PEM) observed. Furthermore, MRIs and functional imaging revealed that resting brain activity normalised during rovunaptabin therapy, with fewer overactive brain areas. The study’s results were published in the journal eClinicalMedicine, part of The Lancet group (Vol. 86, August 2025). Rovunaptabin was provided by APTA Therapeutics for the reCOVer study.